MYC and small cell lung carcinoma: Interestingly, one of the three drugs unique to the cMYC analysis of the NCI database was the CHK1 inhibitor praxasertib (LY-2606368) (FC = 1.9, p = 0.006), which our group has independently been shown to have preferential activity in pre-clinical models of SCLC that overexpress cMYC protein [4].